Hepatitis Monthly

Published by: Kowsar

The CCR5-∆32 Mutation: Impact on Disease Outcome in Individuals with Hepatitis B Infection in the Southern Khorasan Population (East of Iran)

Hamidreza Safari 1 , Gholamreza Anani Sarab 2 , Mohammad Fereidouni 3 , Masood Ziaee 2 , Neda Mahavar 1 , Mohammad Sadegh Naghizadeh 1 , Abdolghader Taene 1 , Roya Mahdavi 4 and Mohsen Naseri 3 , *
Authors Information
1 Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran
2 Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran
3 Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran
4 Department of Immunology, Birjand University of Medical Sciences, Birjand, Iran
Article information
  • Hepatitis Monthly: October 2017, 17 (10); e55014
  • Published Online: October 23, 2017
  • Article Type: Research Article
  • Received: June 14, 2017
  • Revised: September 3, 2017
  • Accepted: October 7, 2017
  • DOI: 10.5812/hepatmon.55014

To Cite: Safari H, Anani Sarab G, Fereidouni M, Ziaee M, Mahavar N, et al. The CCR5-∆32 Mutation: Impact on Disease Outcome in Individuals with Hepatitis B Infection in the Southern Khorasan Population (East of Iran), Hepat Mon. 2017 ; 17(10):e55014. doi: 10.5812/hepatmon.55014.

Abstract
Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Schinazi RF, Asselah T. From HCV To HBV Cure. Liver Int. 2017; 37 Suppl 1: 73-80[DOI][PubMed]
  • 2. Ziaee M, Azarkar G. Prevalence of hepatitis d virus infection among patients with chronic hepatitis B attending birjand hepatitis clinic (East of iran) in 2012. Hepat Mon. 2013; 13(8)[DOI][PubMed]
  • 3. Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: Epidemiology and prevention in developing countries. World J Hepatol. 2012; 4(3): 74-80[DOI][PubMed]
  • 4. Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol. 2011; 17(2): 87-95[DOI][PubMed]
  • 5. McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am. 2014; 98(1): 39-54[DOI][PubMed]
  • 6. Mohebbi SR, Amini-Bavil-Olyaee S, Zali N, Noorinayer B, Derakhshan F, Chiani M, et al. Molecular epidemiology of hepatitis B virus in Iran. Clin Microbiol Infect. 2008; 14(9): 858-66[DOI][PubMed]
  • 7. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005; 54: 1-31[PubMed]
  • 8. WHO . Introduction of hepatitis B vaccine into childhood immunization services. WHO. 2001;
  • 9. Truelove AL, Oleksyk TK, Shrestha S, Thio CL, Goedert JJ, Donfield SM, et al. Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome. Int J Immunogenet. 2008; 35(3): 255-64[DOI][PubMed]
  • 10. Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H. Impact of host gene polymorphisms on susceptibility to chronic hepatitis B virus infection. Infect Genet Evol. 2016; 44: 94-105[DOI][PubMed]
  • 11. Tuncbilek S. Relationship between cytokine gene polymorphisms and chronic hepatitis B virus infection. World J Gastroenterol. 2014; 20(20): 6226-35[DOI][PubMed]
  • 12. Zare-Bidaki M, Karimi-Googheri M, Hassanshahi G, Zainodini N, Arababadi MK. The frequency of CCR5 promoter polymorphisms and CCR5 Delta 32 mutation in Iranian populations. Iran J Basic Med Sci. 2015; 18(4): 312-6[PubMed]
  • 13. Prahalad S. Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun. 2006; 7(3): 264-8[DOI][PubMed]
  • 14. Bobyk KD, Mandadapu SR, Lohith K, Guzzo C, Bhargava A, Lusso P, et al. Design of HIV Coreceptor Derived Peptides That Inhibit Viral Entry at Submicromolar Concentrations. Mol Pharm. 2017; 14(8): 2681-9[DOI][PubMed]
  • 15. Zulfiqar HF, Javed A, Afroze B, Ali Q, Akbar K, et al. HIV Diagnosis and Treatment through Advanced Technologies. Front Public Health. 2017; 5: 32[DOI][PubMed]
  • 16. de Silva E, Stumpf MP. HIV and the CCR5-Delta32 resistance allele. FEMS Microbiol Lett. 2004; 241(1): 1-12[DOI][PubMed]
  • 17. Contopoulos-Ioannidis DG, O'Brien TR, Goedert JJ, Rosenberg PS, Ioannidis JP. Effect of CCR5-delta32 heterozygosity on the risk of perinatal HIV-1 infection: a meta-analysis. J Acquir Immune Defic Syndr. 2003; 32(1): 70-6[DOI][PubMed]
  • 18. Sanchooli J, Sanadgol N, Kazemi Arababadi M, Kennedy D. CCR5 plays important roles in hepatitis B infection. Viral Immunol. 2014; 27(1): 2-6[DOI][PubMed]
  • 19. Lucotte G, Mercier G. Distribution of the CCR5 gene 32-bp deletion in Europe. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 19(2): 174-7[DOI][PubMed]
  • 20. Gharagozloo M, Doroudchi M, Farjadian S, Pezeshki AM, Ghaderi A. The frequency of CCR5Delta32 and CCR2-64I in southern Iranian normal population. Immunol Lett. 2005; 96(2): 277-81[DOI][PubMed]
  • 21. Ziaee M, Ebrahimzadeh A, Azarkar Z, Namaei MH, Saburi A, Fereidouni M, et al. Seroprevalence and Risk Factors for Hepatitis B in an Adult Population: The First Report from Birjand, South Khorasan, Iran. Hepat Mon. 2016; 16(9)[DOI][PubMed]
  • 22. Kazemi Arababadi M, Hassanshahi G, Azin H, Akbarpour Salehabad V, Araste M, Pourali R, et al. No association between CCR5-Δ32 mutation and multiple sclerosis in patients of southeastern Iran. Lab Med. 2010; 41(1): 31-3[DOI]
  • 23. Omrani MD, Bagheri M. Frequency of CCR5Δ32 variant in North-West of Iran. J Sci Islam Repub Iran. 2009; 20(2): 105-10[DOI]
  • 24. Novembre J, Galvani AP, Slatkin M. The geographic spread of the CCR5 Delta32 HIV-resistance allele. PLoS Biol. 2005; 3(11)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments